Ilina C. Odouard
Research Subjects
Ilina C. Odouard has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Gerard Anderson
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205
2 shared publications Jeromie Ballreich
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
2 shared publications- Mariana P. Socal
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205
2 shared publications - A. Chahar
University of Maryland
1 shared publication Betsy Lane
University of Maryland
1 shared publicationBranden Lee
Johns Hopkins University School of Medicine, Baltimore, USA
1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by SAGE Publications in Medical Care Research and Review
- Vol. 83 (6) , 563-572
Changes in Service Delivery Following Site-Neutral Payment Reforms by Hospital 340B Status
Medicare site-dependent payments and the 340B Drug Pricing Program both incentivize vertical integration between hospitals and physician practices. Medicare pays higher rates to hospital outpatient departments (HOPDs) than to physician offices, incentivizing hospitals to acquire and convert standalone physician practices into off-campus HOPDs. 340B hospitals earn enhanced profits from outpatient drug delivery, which may further incentivize acquisition of new sites. We used Medicare fee-for-service claims to describe trends between 2016 and 2022 in services provided at off-campus HOPDs, an indicator of vertical integration, stratified by hospital 340B participation status. 340B hospitals delivered a higher and growing percentage of outpatient services at off-campus HOPDs than non-participating hospitals. Drugs accounted for a larger percentage of off-campus HOPD claims at 340B hospitals. At off-campus HOPDs paid site-neutral rates, service volume increased faster among 340B hospitals. Despite recent reforms, 340B hospitals may be more incentivized to pursue vertical integration than other hospitals.
- 17 June 2026
- Published by SAGE Publications in Medical Care Research and Review
- Vol. 83 (6) , 563-572
Open AccessChanges in Service Delivery Following Site-Neutral Payment Reforms by Hospital 340B Status
Medicare site-dependent payments and the 340B Drug Pricing Program both incentivize vertical integration between hospitals and physician practices. Medicare pays higher rates to hospital outpatient departments (HOPDs) than to physician offices, incentivizing hospitals to acquire and convert standalone physician practices into off-campus HOPDs. 340B hospitals earn enhanced profits from outpatient drug delivery, which may further incentivize acquisition of new sites. We used Medicare fee-for-service claims to describe trends between 2016 and 2022 in services provided at off-campus HOPDs, an indicator of vertical integration, stratified by hospital 340B participation status. 340B hospitals delivered a higher and growing percentage of outpatient services at off-campus HOPDs than non-participating hospitals. Drugs accounted for a larger percentage of off-campus HOPD claims at 340B hospitals. At off-campus HOPDs paid site-neutral rates, service volume increased faster among 340B hospitals. Despite recent reforms, 340B hospitals may be more incentivized to pursue vertical integration than other hospitals.
- Open Access
- 1 July 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (7) , qxaf139
Research and development investments for biologics independently developed by US biotechnology startups, 2017–2023
Introduction: Despite policy interest in pharmaceutical innovation, little is known about the investment needed for venture capital–backed startups to develop innovative biologics, a growing segment of the pharmaceutical marketplace. Methods: In a cross-sectional analysis of Food and Drug Administration (FDA) drug approval data, investment deal records, and clinical trials data, we estimated the investment needed for a biotechnology startup company to independently develop a biologic approved by the US FDA with priority review, an indicator of innovation. To isolate a homogenous set of cases, the sample focused on independent drug development of 13 drugs by 9 biotechnology startup companies that retained ownership of the drug from the start of development to FDA approval without being acquired or licensing the product. Results: We found that the median investment per FDA-approved biologic was $304.1 million (IQR: $289.9–$790.3 million) in uncapitalized costs, accounting for the cost of failures. Conclusion: This estimate represents the direct drug R&D investment needed for independent development of innovative biologic products by biotechnology startup companies.
- 1 July 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (7) , qxaf139
Open AccessResearch and development investments for biologics independently developed by US biotechnology startups, 2017–2023
Introduction: Despite policy interest in pharmaceutical innovation, little is known about the investment needed for venture capital–backed startups to develop innovative biologics, a growing segment of the pharmaceutical marketplace. Methods: In a cross-sectional analysis of Food and Drug Administration (FDA) drug approval data, investment deal records, and clinical trials data, we estimated the investment needed for a biotechnology startup company to independently develop a biologic approved by the US FDA with priority review, an indicator of innovation. To isolate a homogenous set of cases, the sample focused on independent drug development of 13 drugs by 9 biotechnology startup companies that retained ownership of the drug from the start of development to FDA approval without being acquired or licensing the product. Results: We found that the median investment per FDA-approved biologic was $304.1 million (IQR: $289.9–$790.3 million) in uncapitalized costs, accounting for the cost of failures. Conclusion: This estimate represents the direct drug R&D investment needed for independent development of innovative biologic products by biotechnology startup companies.
- 5 August 2024
- Published by Springer Nature in Pediatric Drugs
- Vol. 26 (6) , 741-752
Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions
Background Gene and RNA therapies have potential to transform the treatment of rare inherited diseases, but there are concerns about the evidence supporting their use and high costs. Objective We analyze the evidence supporting Food and Drug Administration (FDA) approval of gene and RNA therapies for rare inherited diseases and discuss implications for clinical practice and policy. Methods We conducted a qualitative analysis of FDA documents outlining the basis of approval for gene and RNA therapies approved for rare inherited diseases between 2016 and 2023. For each drug, we gathered five characteristics of the evidence supporting FDA approval (no phase 3 trial, nonrandomized, no clinical endpoint, lack of demonstrated benefit, and significant protocol deviation) and four characteristics of the FDA approval process (prior rejection or complete response, negative committee vote, discrepancy between label and trial population, and boxed warning). The main outcome was the number of drugs with each characteristic. Results Between 2016 and 2023, 19 gene and RNA therapies received FDA approval to treat rare inherited diseases. The most common limitations in the evidence supporting approval of these drugs were nonrandomized studies (8/19, 42%), no clinical endpoint (7/19, 37%), lack of demonstrated benefit or inconsistent results (4/19, 21%), and no phase 3 trial (4/19, 21%). Half (3/6) of accelerated approvals and 57% (5/9) of drugs with breakthrough designation had nonrandomized trials, and gene therapies with one-time dosing were overrepresented (5/7, 71%) among the drugs with nonrandomized trials. Five of six accelerated approvals (83%) and five of nine pediatric drugs (56%), most of which were indicated for Duchenne muscular dystrophy, had no clinical endpoint. Four of nine (44%) pediatric drugs and four of six (67%) accelerated approvals failed to demonstrate benefit compared with none of the nonpediatric drugs and none of the traditional approvals. Five drugs, which all had different indications and represented a mix of RNA and gene therapies, did not have any of these evidence characteristics. Among drugs that received prior rejections or negative committee opinions, all four had nonrandomized trials and lacked a clinical endpoint, and 75% (3/4) lacked demonstrated benefit. Five of nine (56%) pediatric drugs were indicated for broader age groups according to the drug label compared with the trial populations. Of the three drugs with boxed warnings, two had pediatric indications and nonrandomized studies, and one had no phase 3 trial. Conclusions Issues related to trial design, outcome, and data integrity in the evidence supporting FDA approval of rare inherited disease gene and RNA therapies raise questions about whether this evidence is adequate to inform prescribing decisions. Gene and RNA therapies with accelerated approval and pediatric indications were overrepresented among drugs lacking clinical endpoints or demonstrated benefit and should be the focus of efforts to reduce uncertainty in the evidence.
- 5 August 2024
- Published by Springer Nature in Pediatric Drugs
- Vol. 26 (6) , 741-752
Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions
Background Gene and RNA therapies have potential to transform the treatment of rare inherited diseases, but there are concerns about the evidence supporting their use and high costs. Objective We analyze the evidence supporting Food and Drug Administration (FDA) approval of gene and RNA therapies for rare inherited diseases and discuss implications for clinical practice and policy. Methods We conducted a qualitative analysis of FDA documents outlining the basis of approval for gene and RNA therapies approved for rare inherited diseases between 2016 and 2023. For each drug, we gathered five characteristics of the evidence supporting FDA approval (no phase 3 trial, nonrandomized, no clinical endpoint, lack of demonstrated benefit, and significant protocol deviation) and four characteristics of the FDA approval process (prior rejection or complete response, negative committee vote, discrepancy between label and trial population, and boxed warning). The main outcome was the number of drugs with each characteristic. Results Between 2016 and 2023, 19 gene and RNA therapies received FDA approval to treat rare inherited diseases. The most common limitations in the evidence supporting approval of these drugs were nonrandomized studies (8/19, 42%), no clinical endpoint (7/19, 37%), lack of demonstrated benefit or inconsistent results (4/19, 21%), and no phase 3 trial (4/19, 21%). Half (3/6) of accelerated approvals and 57% (5/9) of drugs with breakthrough designation had nonrandomized trials, and gene therapies with one-time dosing were overrepresented (5/7, 71%) among the drugs with nonrandomized trials. Five of six accelerated approvals (83%) and five of nine pediatric drugs (56%), most of which were indicated for Duchenne muscular dystrophy, had no clinical endpoint. Four of nine (44%) pediatric drugs and four of six (67%) accelerated approvals failed to demonstrate benefit compared with none of the nonpediatric drugs and none of the traditional approvals. Five drugs, which all had different indications and represented a mix of RNA and gene therapies, did not have any of these evidence characteristics. Among drugs that received prior rejections or negative committee opinions, all four had nonrandomized trials and lacked a clinical endpoint, and 75% (3/4) lacked demonstrated benefit. Five of nine (56%) pediatric drugs were indicated for broader age groups according to the drug label compared with the trial populations. Of the three drugs with boxed warnings, two had pediatric indications and nonrandomized studies, and one had no phase 3 trial. Conclusions Issues related to trial design, outcome, and data integrity in the evidence supporting FDA approval of rare inherited disease gene and RNA therapies raise questions about whether this evidence is adequate to inform prescribing decisions. Gene and RNA therapies with accelerated approval and pediatric indications were overrepresented among drugs lacking clinical endpoints or demonstrated benefit and should be the focus of efforts to reduce uncertainty in the evidence.
- Open Access
- 26 April 2024
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 2 (5) , qxae051
Medicaid spending and utilization of gene and RNA therapies for rare inherited conditions
Gene and RNA therapies are promising treatments for many rare diseases. Pediatric populations that could benefit from these drugs are overrepresented among state Medicaid programs. Using Medicaid State Drug Utilization Data, we examined Medicaid spending and utilization of rare disease gene and RNA therapies. Between 2017 and 2022, the number of available gene and RNA therapies increased from 3 to 13, yearly Medicaid spending increased from $148.3 million to $879.7 million, and the number of yearly treatments (a proxy for number of patients) increased from 327 to 1638. Nearly all spending was attributed to spinal muscular atrophy (SMA) and Duchenne muscular dystrophy drugs. States participating in Medicaid pooled purchasing initiatives had 39% higher treatments per 100 000 enrollees with no differences in spending. Compared to states without a carve-out, states that carved SMA drugs out of managed Medicaid contracts had higher utilization (54%). Spending among carve-out states varied according to managed care enrollment, being higher for those with <80% of enrollees in managed care as compared with those with ≥80% of enrollees in managed care. This suggests that multi-state purchasing initiatives and managed care carve-outs can help increase access to gene and RNA therapies among Medicaid beneficiaries, but it is unclear if these strategies are effective at managing spending.
- 26 April 2024
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 2 (5) , qxae051
Open AccessMedicaid spending and utilization of gene and RNA therapies for rare inherited conditions
Gene and RNA therapies are promising treatments for many rare diseases. Pediatric populations that could benefit from these drugs are overrepresented among state Medicaid programs. Using Medicaid State Drug Utilization Data, we examined Medicaid spending and utilization of rare disease gene and RNA therapies. Between 2017 and 2022, the number of available gene and RNA therapies increased from 3 to 13, yearly Medicaid spending increased from $148.3 million to $879.7 million, and the number of yearly treatments (a proxy for number of patients) increased from 327 to 1638. Nearly all spending was attributed to spinal muscular atrophy (SMA) and Duchenne muscular dystrophy drugs. States participating in Medicaid pooled purchasing initiatives had 39% higher treatments per 100 000 enrollees with no differences in spending. Compared to states without a carve-out, states that carved SMA drugs out of managed Medicaid contracts had higher utilization (54%). Spending among carve-out states varied according to managed care enrollment, being higher for those with <80% of enrollees in managed care as compared with those with ≥80% of enrollees in managed care. This suggests that multi-state purchasing initiatives and managed care carve-outs can help increase access to gene and RNA therapies among Medicaid beneficiaries, but it is unclear if these strategies are effective at managing spending.
- 27 October 2023
- Published by Elsevier in Value in Health
- Vol. 26 (11)
Table of Contents